Drug
Oraxol
Oraxol: highest development phase Phase 3, developed by Athenex, United Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Athenex, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Oraxol NCT02594371 | Phase 3 | Metastatic Breast Cancer |
| Oraxol NCT03544567 | Phase 2 | Angiosarcoma of Skin |
| Oraxol NCT04180384 | Phase 2 | Solid Tumor |
| Oraxol NCT02970539 | Phase 1 | Gastric Cancer |
| Oraxol NCT04993040 | Phase 1 | Breastcancer |
| Oraxol NCT04168957 | Phase 1 | Breastcancer |
| Oraxol NCT01967043 | Phase 1 | Solid Tumor |
| Oraxol NCT03588039 | Phase 1 | Solid Tumor |
| Oraxol NCT02730481 | Phase 1 | Solid Tumor |
| Oraxol NCT03892018 | Phase 1 | Solid Tumor, Adult |
Latest
No recent events.
Follow Oraxol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.